

# John M Koomen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4223989/publications.pdf>

Version: 2024-02-01

94  
papers

5,169  
citations

87888

38  
h-index

95266

68  
g-index

96  
all docs

96  
docs citations

96  
times ranked

9235  
citing authors

#	ARTICLE	IF	CITATIONS
1	The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. <i>Cell Chemical Biology</i> , 2022, 29, 202-214.e7.	5.2	19
2	Integrated Proteomics-Based Physical and Functional Mapping of AXL Kinase Signaling Pathways and Inhibitors Define Its Role in Cell Migration. <i>Molecular Cancer Research</i> , 2022, 20, 542-555.	3.4	2
3	Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Energy. <i>Cancer Research</i> , 2022, 82, 1234-1250.	0.9	8
4	Deubiquitinase Vulnerabilities Identified through Activity-Based Protein Profiling in Non-Small Cell Lung Cancer. <i>ACS Chemical Biology</i> , 2022, 17, 776-784.	3.4	1
5	Macrophages use apoptotic cell-derived methionine and DNMT3A during efferocytosis to promote tissue resolution. <i>Nature Metabolism</i> , 2022, 4, 444-457.	11.9	56
6	Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. <i>Clinical Cancer Research</i> , 2022, 28, 2131-2146.	7.0	36
7	Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor-Resistant Melanoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 840-851.e4.	0.7	19
8	Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition. <i>Clinical Cancer Research</i> , 2021, 27, 2533-2548.	7.0	46
9	Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4012-4024.	7.0	20
10	A Mutational Survey of Acral Nevi. <i>JAMA Dermatology</i> , 2021, 157, 831-835.	4.1	13
11	Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma. <i>Journal of Proteome Research</i> , 2021, 20, 3134-3149.	3.7	11
12	Fucosylated Proteome Profiling Identifies a Fucosylated, Non-Ribosomal, Stress-Responsive Species of Ribosomal Protein S3. <i>Cells</i> , 2021, 10, 1310.	4.1	4
13	Targeted mass-spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP kinase, and AKT signaling. <i>Cell Reports Methods</i> , 2021, 1, 100015.	2.9	10
14	Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 5477-5490.	0.9	48
15	Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1410-1418.	30.7	168
16	Managing a Large-Scale Multiomics Project: A Team Science Case Study in Proteogenomics. <i>Methods in Molecular Biology</i> , 2021, 2194, 187-221.	0.9	0
17	Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. <i>JCI Insight</i> , 2021, 6, .	5.0	8
18	GMSimpute: a generalized two-step Lasso approach to impute missing values in label-free mass spectrum analysis. <i>Bioinformatics</i> , 2020, 36, 257-263.	4.1	13

#	ARTICLE	IF	CITATIONS
19	Translational pathology, genomics and the development of systemic therapies for acral melanoma. <i>Seminars in Cancer Biology</i> , 2020, 61, 149-157.	9.6	30
20	Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance. <i>Clinical Cancer Research</i> , 2020, 26, 2163-2175.	7.0	39
21	Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes. <i>Blood</i> , 2020, 136, 857-870.	1.4	18
22	Lowering Sample Requirements to Study Tyrosine Kinase Signaling Using Phosphoproteomics with the TMT Calibrator Approach. <i>Proteomics</i> , 2020, 20, e2000116.	2.2	12
23	Macrophage Metabolism of Apoptotic Cell-Derived Arginine Promotes Continual Efferocytosis and Resolution of Injury. <i>Cell Metabolism</i> , 2020, 31, 518-533.e10.	16.2	235
24	HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms. <i>Blood</i> , 2020, 135, 191-207.	1.4	40
25	TAp63-Regulated miRNAs Suppress Cutaneous Squamous Cell Carcinoma through Inhibition of a Network of Cell-Cycle Genes. <i>Cancer Research</i> , 2020, 80, 2484-2497.	0.9	16
26	Proteogenomic landscape of squamous cell lung cancer. <i>Nature Communications</i> , 2019, 10, 3578.	12.8	84
27	Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets. <i>Cell Chemical Biology</i> , 2019, 26, 1240-1252.e11.	5.2	15
28	HDAC Inhibition Enhances the <i>In Vivo</i> Efficacy of MEK Inhibitor Therapy in Uveal Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 5686-5701.	7.0	75
29	Proteometabolomics of Melphalan Resistance in Multiple Myeloma. <i>Methods in Molecular Biology</i> , 2019, 1996, 273-296.	0.9	6
30	BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. <i>Cancer Cell</i> , 2019, 35, 752-766.e9.	16.8	56
31	K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling. <i>Nature Communications</i> , 2019, 10, 1870.	12.8	61
32	HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy. <i>Cancer Research</i> , 2019, 79, 2947-2961.	0.9	59
33	An immunoproteomic approach to characterize the CAR interactome and signalosome. <i>Science Signaling</i> , 2019, 12, .	3.6	109
34	<i>PTPN11</i> Plays Oncogenic Roles and Is a Therapeutic Target for <i>BRAF</i> Wild-Type Melanomas. <i>Molecular Cancer Research</i> , 2019, 17, 583-593.	3.4	34
35	Combined BRAF and HSP90 Inhibition in Patients with Unresectable <i>BRAF</i> V600E-Mutant Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 5516-5524.	7.0	55
36	Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. <i>Journal of Proteome Research</i> , 2018, 17, 63-75.	3.7	18

#	ARTICLE	IF	CITATIONS
37	Cytokeratin-8 in Anaplastic Thyroid Carcinoma: More Than a Simple Structural Cytoskeletal Protein. <i>International Journal of Molecular Sciences</i> , 2018, 19, 577.	4.1	13
38	PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. <i>Journal of Clinical Investigation</i> , 2018, 128, 5517-5530.	8.2	67
39	Quantitative proteomics of breast tumors: Tissue quality assessment to clinical biomarkers. <i>Proteomics</i> , 2017, 17, 1600335.	2.2	8
40	Relative protein quantification and accessible biology in lung tumor proteomes from four LC-MS/MS discovery platforms. <i>Proteomics</i> , 2017, 17, 1600300.	2.2	15
41	Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. <i>Nature Communications</i> , 2017, 8, 14920.	12.8	122
42	Polypharmacology-based ceritinib repurposing using integrated functional proteomics. <i>Nature Chemical Biology</i> , 2017, 13, 1222-1231.	8.0	60
43	Multiplexed Liquid Chromatography-Multiple Reaction Monitoring Mass Spectrometry Quantification of Cancer Signaling Proteins. <i>Methods in Molecular Biology</i> , 2017, 1647, 19-45.	0.9	5
44	Quantification of Breast Cancer Protein Biomarkers at Different Expression Levels in Human Tumors. <i>Methods in Molecular Biology</i> , 2017, 1788, 251-268.	0.9	2
45	Inhibition of PI3K/Akt/mTOR signaling in PI3KR2-overexpressing colon cancer stem cells reduces tumor growth due to apoptosis. <i>Oncotarget</i> , 2017, 8, 50476-50488.	1.8	43
46	Activity-Based Proteomics Reveals Heterogeneous Kinome and ATP-Binding Proteome Responses to MEK Inhibition in KRAS Mutant Lung Cancer. <i>Proteomes</i> , 2016, 4, 16.	3.5	5
47	Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. <i>Clinical Cancer Research</i> , 2016, 22, 5605-5616.	7.0	19
48	APOSTL: An Interactive Galaxy Pipeline for Reproducible Analysis of Affinity Proteomics Data. <i>Journal of Proteome Research</i> , 2016, 15, 4747-4754.	3.7	16
49	Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition. <i>Journal of Proteome Research</i> , 2016, 15, 4476-4489.	3.7	16
50	Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. <i>Molecular Cancer Research</i> , 2016, 14, 1019-1029.	3.4	53
51	Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. <i>Cell Chemical Biology</i> , 2016, 23, 1490-1503.	5.2	80
52	Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 334-342.	4.1	19
53	Identification of Target Pathways Induced By the Multiple Myeloma Tumor Microenvironment Using Activity-Based Protein Profiling and Ex Vivo Protein Kinase Inhibitor Screening. <i>Blood</i> , 2016, 128, 3288-3288.	1.4	0
54	Chronic acidosis in the tumour microenvironment selects for overexpression of LAMP2 in the plasma membrane. <i>Nature Communications</i> , 2015, 6, 8752.	12.8	151

#	ARTICLE	IF	CITATIONS
55	Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma. <i>Oncotarget</i> , 2015, 6, 6191-6202.	1.8	39
56	Quantitative analysis of immunoglobulin subclasses and subclass specific glycosylation by LC-MS/MS in liver disease. <i>Journal of Proteomics</i> , 2015, 116, 24-33.	2.4	67
57	Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy-Mediated Metastatic Melanoma Phenotype. <i>Cancer Discovery</i> , 2015, 5, 264-273.	9.4	82
58	Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides. <i>Methods</i> , 2015, 81, 41-49.	3.8	11
59	Ubiquitinated Sirtuin 1 (SIRT1) Function Is Modulated during DNA Damage-induced Cell Death and Survival. <i>Journal of Biological Chemistry</i> , 2015, 290, 8904-8912.	3.4	50
60	A Pilot Proteogenomic Study with Data Integration Identifies MCT1 and GLUT1 as Prognostic Markers in Lung Adenocarcinoma. <i>PLoS ONE</i> , 2015, 10, e0142162.	2.5	31
61	Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 1844-1854.	3.8	52
62	Adaptive Responses to Dasatinib-Treated Lung Squamous Cell Cancer Cells Harboring DDR2 Mutations. <i>Cancer Research</i> , 2014, 74, 7217-7228.	0.9	43
63	Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4059-4074.	7.0	95
64	Quantification of peptides from immunoglobulin constant and variable regions by LC-MS/MS for assessment of multiple myeloma patients. <i>Proteomics - Clinical Applications</i> , 2014, 8, 783-795.	1.6	33
65	Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma. <i>Melanoma Research</i> , 2014, 24, 448-453.	1.2	14
66	Immunoglobulins: Expanding the Role for Mass Spectrometry in Protein Biomarker Quantification. <i>Clinical Chemistry</i> , 2014, 60, 1034-1035.	3.2	2
67	Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an <i>In Vivo</i> Model of NRAS-Mutant Melanoma. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 901-912.	4.1	52
68	Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 12414-12419.	7.1	88
69	The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms. <i>Clinical Cancer Research</i> , 2012, 18, 2502-2514.	7.0	145
70	GSK3 $\beta$ Inhibition Blocks Melanoma Cell/Host Interactions by Downregulating N-Cadherin Expression and Decreasing FAK Phosphorylation. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2818-2827.	0.7	37
71	An ET-CURE Pilot Project Supporting Undergraduate Training in Cancer Research, Emerging Technology, and Health Disparities. <i>Journal of Cancer Education</i> , 2012, 27, 418-427.	1.3	4
72	Evaluation of Direct Infusion-Multiple Reaction Monitoring Mass Spectrometry for Quantification of Heat Shock Proteins. <i>Analytical Chemistry</i> , 2012, 84, 1981-1986.	6.5	12

#	ARTICLE	IF	CITATIONS
73	A mass spectrometry-based method to screen for $\pm$ -amidated peptides. <i>Proteomics</i> , 2012, 12, 173-182.	2.2	13
74	Evaluation of protein quantification using standard peptides containing single conservative amino acid replacements. <i>Journal of Mass Spectrometry</i> , 2012, 47, 188-194.	1.6	13
75	Mass Spectrometry Mapping of Epidermal Growth Factor Receptor Phosphorylation Related to Oncogenic Mutations and Tyrosine Kinase Inhibitor Sensitivity. <i>Journal of Proteome Research</i> , 2011, 10, 305-319.	3.7	56
76	A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. <i>Proteomics - Clinical Applications</i> , 2011, 5, 383-396.	1.6	48
77	PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression. <i>Cancer Research</i> , 2011, 71, 2750-2760.	0.9	488
78	Monitoring a Nuclear Factor- $\kappa$ B Signature of Drug Resistance in Multiple Myeloma. <i>Molecular and Cellular Proteomics</i> , 2011, 10, M110.005520.	3.8	30
79	Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling. <i>Biochemical Pharmacology</i> , 2010, 80, 739-747.	4.4	15
80	A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. <i>Nature Chemical Biology</i> , 2010, 6, 291-299.	8.0	254
81	Urine Collection and Processing for Protein Biomarker Discovery and Quantification. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 953-959.	2.5	110
82	IKK $\mu$ Phosphorylation of Estrogen Receptor $\pm$ Ser-167 and Contribution to Tamoxifen Resistance in Breast Cancer. <i>Journal of Biological Chemistry</i> , 2010, 285, 3676-3684.	3.4	48
83	Critical Role of Shp2 in Tumor Growth Involving Regulation of c-Myc. <i>Genes and Cancer</i> , 2010, 1, 994-1007.	1.9	28
84	Quantification of $\beta$ -Catenin Signaling Components in Colon Cancer Cell Lines, Tissue Sections, and Microdissected Tumor Cells using Reaction Monitoring Mass Spectrometry. <i>Journal of Proteome Research</i> , 2010, 9, 4215-4227.	3.7	45
85	IPEP: an <i>in silico</i> tool to examine proteolytic peptides for mass spectrometry. <i>Bioinformatics</i> , 2008, 24, 2801-2802.	4.1	11
86	Proteomic Contributions to Personalized Cancer Care. <i>Molecular and Cellular Proteomics</i> , 2008, 7, 1780-1794.	3.8	89
87	Proteome Analysis of Isolated Perfused Organ Effluent as a Novel Model for Protein Biomarker Discovery. <i>Journal of Proteome Research</i> , 2006, 5, 177-182.	3.7	23
88	Diagnostic protein discovery using liquid chromatography/mass spectrometry for proteolytic peptide targeting. <i>Rapid Communications in Mass Spectrometry</i> , 2005, 19, 1624-1636.	1.5	15
89	Understanding the Characteristics of Mass Spectrometry Data through the use of Simulation. <i>Cancer Informatics</i> , 2005, 1, 117693510500100.	1.9	42
90	Direct Tandem Mass Spectrometry Reveals Limitations in Protein Profiling Experiments for Plasma Biomarker Discovery. <i>Journal of Proteome Research</i> , 2005, 4, 972-981.	3.7	210

#	ARTICLE	IF	CITATIONS
91	Developing an Understanding of Proteomics: An Introduction to Biological Mass Spectrometry. <i>Cancer Investigation</i> , 2005, 23, 47-59.	1.3	13
92	Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. <i>Clinical Cancer Research</i> , 2005, 11, 1110-8.	7.0	125
93	Developing an understanding of proteomics: an introduction to biological mass spectrometry. <i>Cancer Investigation</i> , 2005, 23, 47-59.	1.3	1
94	Diagnostic protein discovery using proteolytic peptide targeting and identification. <i>Rapid Communications in Mass Spectrometry</i> , 2004, 18, 2537-2548.	1.5	26